Reprogenix Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $70.3M

  • Investors
  • 14

Reprogenix General Information

Description

Developer of stem cell therapies designed to treat major diseases through regenerative medicine. The company's technology utilizes a proprietary human pluripotent stem cell platform, stem cell line establishment, directed differentiation, gene editing, molecular detection, and sequencing data analysis, providing healthcare providers with islet cell injections and regenerative medicine products to enable the functional cure of chronic conditions.

Contact Information

Website
www.reprogenix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3rd Floor, Building 2, Hongyan Park, Future Research and Innovation Park
  • Number 138 Wuchang Avenue, Yuhang District
  • Hangzhou, Zhejiang 311100
  • China
+86 400
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 3rd Floor, Building 2, Hongyan Park, Future Research and Innovation Park
  • Number 138 Wuchang Avenue, Yuhang District
  • Hangzhou, Zhejiang 311100
  • China
+86 400

Reprogenix Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Reprogenix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series A1) 20-Nov-2025 $70.3M Completed Generating Revenue
1. Later Stage VC (Series A) 01-Nov-2024 Completed Generating Revenue
To view Reprogenix’s complete valuation and funding history, request access »

Reprogenix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Reprogenix Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Beijing Gage Capital Asset Manager Minority
Guoxin Science and Technology Innovation Fund Management Other Private Equity Minority
Hangzhou Dongfang Jiafu Asset Management Venture Capital Minority
Hangzhou Yuhang State-owned Capital Investment and Operation Group Government Minority
Jiangsu Huarui Investment PE/Buyout Minority
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial

Reprogenix FAQs

  • When was Reprogenix founded?

    Reprogenix was founded in 2014.

  • Where is Reprogenix headquartered?

    Reprogenix is headquartered in Hangzhou, China.

  • What is the size of Reprogenix?

    Reprogenix has 19 total employees.

  • What industry is Reprogenix in?

    Reprogenix’s primary industry is Drug Discovery.

  • Is Reprogenix a private or public company?

    Reprogenix is a Private company.

  • What is Reprogenix’s current revenue?

    The current revenue for Reprogenix is .

  • How much funding has Reprogenix raised over time?

    Reprogenix has raised $84.4M.

  • Who are Reprogenix’s investors?

    Beijing Gage Capital, Guoxin Science and Technology Innovation Fund Management, Hangzhou Dongfang Jiafu Asset Management, Hangzhou Yuhang State-owned Capital Investment and Operation Group, and Jiangsu Huarui Investment are 5 of 14 investors who have invested in Reprogenix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process